心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2022 ESC立场声明：药物基因组学在当代心血管治疗中的作用

2022-01-05 欧洲心脏病学会 Eur Heart J Cardiovasc Pharmacother

心血管治疗药物基因组学

2022年1月，欧洲心脏病学会(ESC)心血管药物治疗组发布了药物基因组学在当代心血管治疗中的作用声明。关于药物基因组学在心血管药理学中的应用，有大量且不断增长的证据。

中文标题：

2022 ESC立场声明：药物基因组学在当代心血管治疗中的作用

英文标题：

The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

发布机构：

欧洲心脏病学会

发布日期：

2022-01-05

简要介绍：

2022年1月，欧洲心脏病学会(ESC)心血管药物治疗组发布了药物基因组学在当代心血管治疗中的作用声明。关于药物基因组学在心血管药理学中的应用，有大量且不断增长的证据。本文主要介绍了药物基因组学在当代心血管治疗中的作用，内容涉及抗凝药、抗血小板药、他汀类药物、β阻滞剂、高血压、心率律是从以及化疗引起的心肌病和临床试验。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 ESC立场声明：药物基因组学在当代心血管治疗中的作用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c1df61c00231a909, title=2022 ESC立场声明：药物基因组学在当代心血管治疗中的作用, enTitle=The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, guiderFrom=Eur Heart J Cardiovasc Pharmacother, authorId=0, author=, summary=2022年1月，欧洲心脏病学会(ESC)心血管药物治疗组发布了药物基因组学在当代心血管治疗中的作用声明。关于药物基因组学在心血管药理学中的应用，有大量且不断增长的证据。, cover=https://img.medsci.cn/2022110/1641816208790_1608702.png, journalId=0, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会，会员超过70000人、提供更新指南、调查数据、组织学术会议，ESC年会是心血管领域最大的会议。下设5个分会（超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会）。提供指南较全面，按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Wed Jan 05 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年1月，欧洲心脏病学会(ESC)心血管药物治疗组发布了药物基因组学在当代心血管治疗中的作用声明。关于药物基因组学在心血管药理学中的应用，有大量且不断增长的证据。本文主要介绍了药物基因组学在当代心血管治疗中的作用，内容涉及抗凝药、抗血小板药、他汀类药物、&beta;阻滞剂、高血压、心率律是从以及化疗引起的心肌病和临床试验。</span></p>, tagList=[TagDto(tagId=55258, tagName=心血管治疗), TagDto(tagId=57675, tagName=药物基因组学)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=55258, guiderKeyword=心血管治疗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4026, appHits=61, showAppHits=0, pcHits=428, showPcHits=3965, likes=0, shares=6, comments=5, approvalStatus=1, publishedTime=Mon Jan 10 20:00:02 CST 2022, publishedTimeString=2022-01-05, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Jan 10 20:04:27 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 21:24:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 ESC立场声明：药物基因组学在当代心血管治疗中的作用.pdf)])
2022 ESC立场声明：药物基因组学在当代心血管治疗中的作用.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1200892, encodeId=0f39120089211, content=学习了，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53556543397, createdName=ms2000000463866962, createdTime=Wed Mar 09 14:53:39 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193904, encodeId=90511193904cc, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185999, encodeId=8ee11185999ee, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLTVDib2xrpBM58olojgNLLuxicibcxHqFlXsibCyKNJoefEIGl0KXhyUVugZQNzr7HjrFCHdeKQT2Dlw/0, createdBy=e9a82167028, createdName=半步一生, createdTime=Wed Jan 19 13:26:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182962, encodeId=fedb11829627a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:26:48 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-03-09 ms2000000463866962

    学习了，谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1200892, encodeId=0f39120089211, content=学习了，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53556543397, createdName=ms2000000463866962, createdTime=Wed Mar 09 14:53:39 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193904, encodeId=90511193904cc, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185999, encodeId=8ee11185999ee, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLTVDib2xrpBM58olojgNLLuxicibcxHqFlXsibCyKNJoefEIGl0KXhyUVugZQNzr7HjrFCHdeKQT2Dlw/0, createdBy=e9a82167028, createdName=半步一生, createdTime=Wed Jan 19 13:26:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182962, encodeId=fedb11829627a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:26:48 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-02-16 龙珠

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1200892, encodeId=0f39120089211, content=学习了，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53556543397, createdName=ms2000000463866962, createdTime=Wed Mar 09 14:53:39 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193904, encodeId=90511193904cc, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185999, encodeId=8ee11185999ee, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLTVDib2xrpBM58olojgNLLuxicibcxHqFlXsibCyKNJoefEIGl0KXhyUVugZQNzr7HjrFCHdeKQT2Dlw/0, createdBy=e9a82167028, createdName=半步一生, createdTime=Wed Jan 19 13:26:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182962, encodeId=fedb11829627a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:26:48 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-19 半步一生

    学习了。谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1200892, encodeId=0f39120089211, content=学习了，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53556543397, createdName=ms2000000463866962, createdTime=Wed Mar 09 14:53:39 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193904, encodeId=90511193904cc, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185999, encodeId=8ee11185999ee, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLTVDib2xrpBM58olojgNLLuxicibcxHqFlXsibCyKNJoefEIGl0KXhyUVugZQNzr7HjrFCHdeKQT2Dlw/0, createdBy=e9a82167028, createdName=半步一生, createdTime=Wed Jan 19 13:26:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182962, encodeId=fedb11829627a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:26:48 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-10 ms4000001034418498

    学习

    0